GAMMA Investing’s AgomAb Therapeutics NV AGMB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$15.5K Buy
1,396
+52
+4% +$673 ﹤0.01% 3092
2026
Q2
$17.4K Buy
+1,344
New +$15.1K ﹤0.01% 2912

Other funds holding AGMB

GAMMA Investing's AGMB Position: Q3 2026 in Review

GAMMA Investing increased its AgomAb Therapeutics NV (AGMB) stake by 3.9% in Q3 2026, buying an estimated $673 and bringing the position to 1,396 shares worth $15.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3092.

GAMMA Investing first reported a position in AGMB in Q2 2026 and has held it in 2 quarters since. The position peaked at $17.4K in Q2 2026. 25 funds tracked by Wall St. Rank hold AGMB as of Q3 2026.

  • GAMMA Investing held 1,396 shares of AgomAb Therapeutics NV worth $15.5K as of Q3 2026.
  • GAMMA Investing bought 52 AgomAb Therapeutics NV shares in Q3 2026, an estimated $673.
  • AgomAb Therapeutics NV made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3092 holding.
  • GAMMA Investing first reported a position in AgomAb Therapeutics NV in Q2 2026 and has held it in 2 quarters since.
  • GAMMA Investing's AgomAb Therapeutics NV position peaked at $17.4K in Q2 2026.
  • 25 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.